)
Edge15 May 2026
TOMRA: Closing the Loop
The story of TOMRA: from reverse vending machine pioneer to global technology for deposit systems, recycling, and resource optimization.
KalVista Pharmaceuticals
KalVista Pharmaceuticals (KALV) investor relations material
KalVista Pharmaceuticals Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary14 May, 2026
Executive summary
EKTERLY (sebetralstat) received FDA approval in July 2025 and is now marketed in the U.S., Germany, and Japan, with additional global partnerships established.
A definitive merger agreement was signed with Chiesi Farmaceutici S.p.A. in April 2026, with the transaction expected to close in Q3 2026.
The company operates as a single business segment focused on rare disease therapies.
Financial highlights
Total revenues for Q1 2026 were $40.9 million, up from $0 in Q1 2025, driven by EKTERLY's commercial launch.
Net loss for Q1 2026 was $23.5 million, a significant improvement from a $51.8 million net loss in Q1 2025.
Cash, cash equivalents, and marketable securities totaled $285.0 million as of March 31, 2026.
Operating expenses increased to $64.3 million in Q1 2026 from $49.7 million in Q1 2025, mainly due to higher SG&A costs.
Research and development expenses decreased by 12% year-over-year to $12.4 million.
Outlook and guidance
Management expects continued losses as commercialization of EKTERLY expands.
Current liquidity is anticipated to fund operations for at least the next twelve months.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from KalVista Pharmaceuticals
- EKTERLY's rapid global uptake and robust data position it as a leading HAE therapy.KALV
25th Annual Needham Virtual Healthcare Conference15 Apr 2026 - Rapid revenue growth, global adoption, and strong cash reserves support future expansion.KALVTransition period25 Mar 2026
- EKTERLY's oral HAE therapy drives rapid adoption and global expansion, reshaping the market.KALVCorporate presentation25 Mar 2026
- Oral on-demand HAE therapy adoption accelerates, boosting treatment rates and market growth.KALVThe Citizens Life Sciences Conference 202611 Mar 2026
- Ekterly's rapid adoption and high satisfaction are fueling strong refill-driven revenue growth.KALVTD Cowen 46th Annual Health Care Conference4 Mar 2026
- Sebetralstat's rapid, broad efficacy and global launch plans aim to transform HAE treatment.KALV2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026
- Sebetralstat targets a $900M+ HAE market with a June 2025 US launch and global expansion planned.KALVStifel 2024 Healthcare Conference13 Jan 2026
- Oral HAE therapy sebetralstat nears approval, poised to transform on-demand treatment.KALVJefferies London Healthcare Conference 202413 Jan 2026
- EKTERLY's oral HAE therapy drives rapid growth, global expansion, and a robust rare disease pipeline.KALVCorporate Presentation9 Jan 2026
Next KalVista Pharmaceuticals earnings date
Q4 20269 Jul, 2026
KalVista Pharmaceuticals
Next KalVista Pharmaceuticals earnings date
Q4 20269 Jul, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage